Evidence map›Paper›PMID 19961314›Full record

ArticleJournal of neurosurgery2010

Protection against focal ischemic injury to the brain by trans-sodium crocetinate. Laboratory investigation.

Hiroaki Manabe, David O Okonkwo, John L Gainer, Ryon H Clarke, Kevin S Lee

Abstract read
In one paragraph

Article in Journal of neurosurgery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Review
  3. PRIMEDTranslational stroke research · 2022
    Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Hiroaki ManabeDepartment of Neuroscience, University of Virginia, Charlottesville, Virginia 22908, USA. ksl3h@virginia.edu
David O Okonkwo
John L Gainer
Ryon H Clarke
Kevin S Lee
Neurological Surgery · USUniversity of Virginia · USBiochemical Society · GB

Funding

PREDOCTORAL TRAINING IN NEUROSCIENCET32GM008328 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI LEE, KEVIN SCOTT · 1992 to 2017
$3.9M
Utility of a Novel Carotenoid for Treating StrokeR01NS057168 · NINDS · UNIVERSITY OF VIRGINIA · PI LEE, KEVIN SCOTT · 2008 to 2010
$956k
NIGMS NIH HHS T32 GM008328NIGMS NIH HHS T32 GM08328NINDS NIH HHS NS057168NINDS NIH HHS R01 NS057168
6 · The paper itself

Abstract

objectIschemic injury is a potential complication in a variety of surgical procedures and is a particular impediment to the success of surgeries involving highly vulnerable neural tissue. One approach to limiting this form of injury is to enhance metabolic supply to the affected tissue. Trans-sodium crocetinate (TSC) is a carotenoid compound that has been shown to increase tissue oxygenation by facilitating the diffusivity of small molecules, such as oxygen and glucose. The present study examined the ability of TSC to modify oxygenation in ischemic neural tissue and tested the potential neuroprotective effects of TSC in permanent and temporary models of focal cerebral ischemia.

methodsAdult male rats (330–370 g) were subjected to either permanent or temporary focal ischemia by simultaneous occlusion of both common carotid arteries and the left middle cerebral artery (3-vessel occlusion [3-VO]). Using the permanent ischemia paradigm, TSC was administered intravenously beginning 10 minutes after the onset of ischemia at 1 of 8 dosages, ranging from 0.023 to 4.580 mg/kg. Cerebral infarct volume was measured 24 hours after the onset of ischemia. The effect of TSC on infarct volume was also tested after temporary (2-hour) ischemia using a dosage of 0.092 mg/kg. In other animals undergoing temporary ischemia, tissue oxygenation was monitored in the ischemic penumbra using a Licox probe.

resultsAdministration of TSC reduced infarct volume in a dose-dependent manner in the permanent ischemia model, achieving statistical significance at dosages ranging from 0.046 to 0.229 mg/kg. The most effective dosage of TSC in the permanent ischemia experiment (0.092 mg/kg) was further tested using a temporary (2-hour) ischemia paradigm. Infarct volume was reduced significantly by TSC in this ischemia-reperfusion model as well. Recordings of oxygen levels in the ischemic penumbra of the temporary ischemia model showed that TSC increased tissue oxygenation during vascular occlusion, but reduced the oxygen overshoot (hyperoxygenation) that occurs upon reperfusion.

conclusionsThe novel carotenoid compound TSC exerts a neuroprotective influence against permanent and temporary ischemic injury when administered soon after the onset of ischemia. The protective mechanism of TSC remains to be confirmed; however, the permissive effect of TSC on the diffusivity of small molecules is a plausible mechanism based on the observed increase in tissue oxygenation in the ischemic penumbra. This represents a form of protection based on “metabolic reflow” that can occur under conditions of partial vascular perfusion. It is particularly noteworthy that TSC could conceivably limit the progression of a wide variety of cellular injury mechanisms by blunting the ischemic challenge to the brain.

Indexed as

AnimalsBrainBrain ChemistryBrain IschemiaCarotenoidsCarotid Artery, CommonCerebral InfarctionCerebrovascular CirculationDose-Response Relationship, DrugHemodynamicsIschemic Attack, TransientLigationMaleOxygen ConsumptionRatsRats, Sprague-DawleyCarotenoidstrans-sodium crocetinateVitamin A

Identifiers

PMID19961314
PMCPMC3380430
OpenAlexW1995201681

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.